Peripheral T-cell lymphoma
Francine M Foss1, Pier Luigi Zinzani, Julie M Vose
1Yale Cancer Center, New Haven, CT, USA. francine.foss@yale.edu
Abstract:
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically on PTCL are emerging, with the ultimate goal of improved understanding of disease biology and the development of more effective therapies. However, one of the difficulties in classifying and studying treatment options in clinical trials is the rarity of these subtypes. Various groups have developed lymphoma classifications over the years, including the World Health Organization, which updated its classification in 2008. This article briefly reviews the major lymphoma classification schema, highlights contributions made by the collaborative International PTCL Project, discusses prognostic issues and gene expression profiling, and outlines therapeutic approaches to PTCL. These include the standard chemotherapeutic regimens and other modalities incorporating antifolates, conjugates, histone deacetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling inhibitors. As this review emphasizes, the problem has now evolved into an abundance of drugs and too few patients available to test them. Collaborative groups will aid in future efforts to find the best treatment strategies to improve the outcome for patients with PTCL.
Insights
Peripheral T-cell lymphomas (PTCLs) are aggressive cancers with poor prognoses. Rare subtypes and a growing number of therapies necessitate collaborative research for effective treatment strategies.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Peripheral T-cell lymphomas (PTCLs) represent a diverse and aggressive group of lymphoid malignancies.
- These cancers are characterized by poor patient outcomes and present significant challenges in clinical research due to subtype rarity.
Purpose of the Study:
- To review current lymphoma classification systems, focusing on the International PTCL Project's contributions.
- To discuss prognostic factors, gene expression profiling, and emerging therapeutic strategies for PTCL.
Main Methods:
- Review of major lymphoma classification schemas, including the World Health Organization's 2008 update.
- Analysis of contributions from the International PTCL Project.
- Overview of current and investigational therapeutic modalities.
Main Results:
- The rarity of PTCL subtypes complicates clinical trial enrollment and drug development.
- A wide array of novel therapeutic agents are available, including antifolates, conjugates, and targeted inhibitors.
- The challenge lies in matching patients to appropriate trials due to limited patient populations.
Conclusions:
- Collaborative research efforts are crucial for advancing the understanding and treatment of PTCL.
- Coordinated studies will facilitate the testing of numerous drugs and the identification of optimal treatment strategies.
- Improving outcomes for patients with PTCL requires a unified approach to clinical research and drug evaluation.
Related Concept Videos
01:15Secondary Lymphoid Organs
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
01:16Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
01:18Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...